Lipofermata

Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM[1][2][3].

Product Specifications

CAS Number

[297180-15-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H332, H335

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/lipofermata.html

Purity

99.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1NC2=C(C=C(Br)C=C2)C13SC(C4=CC=CC=C4)=NN3

Molecular Formula

C15H10BrN3OS

Molecular Weight

360.23

Precautions

H302, H315, H319, H332, H335

References & Citations

[1]Falconer SB, et al. Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing Klebsiella pneumoniae. ACS Infect Dis. 2015;1 (11) :533-543.|[2]Sandoval A, et al. Identification and characterization of small compound inhibitors of human FATP2 [published correction appears in Biochem Pharmacol. 2012 Aug 15;84 (4) :580]. Biochem Pharmacol. 2010;79 (7) :990-999. |[3]Ahowesso C, Black PN, Saini N, et al. Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. Biochem Pharmacol. 2015;98 (1) :167-181.